** Shares of Aroa Biosurgery ARX.AX rise 14.9% to A$0.540, their highest levels since February 27
** Stock set for its strongest session since October 22, 2024 - if current trends hold
** The soft-tissue regeneration products maker posts normalised FY EBITDA profit of NZ$4.2 million ($2.50 million) compared to an EBITDA loss NZ$3.1 million last year
** Co sees FY26 normalised EBITDA of NZ$5 million - NZ$8 million
** Stock on track for fifth consecutive session of gains, if current trends hold
** Stock down 29.9% YTD, including current session's moves
($1 = 1.6787 New Zealand dollars)
(Reporting by Manasi Dasa in Bengaluru)
((Manasi.DasaSundeep@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.